• Yeo-Pyo Yun
  • Hwan-Soo Yoo
  • Yoon-Seok Roh
Yeo-Pyo Yun


1976-1980: BS, College of Pharmacy, Seoul National University
1980-1982: MS, College of Pharmacy, Seoul National University
1982-1986: Ph.D, Division of Life Pharmacy, Seoul National University
1988-1990: Post-Doc, National Institutes of Health, USA


1986-1995: Assistant & Associate Professor, College of Pharmacy, Chungbuk National University
1995-present: Professor, College of Pharmacy, Chungbuk National University
2000-2002: Dean, College of Pharmacy, Chungbuk National University
2004-2006: Director, Research Institute for Development of Pharmaceutical Resources, Chungbuk National University
2001-2003: Vice President, The Pharmaceutical Society of Korea
2007-2009: Vice President, The Korean Society of Food Hygiene and Safety
1998-present: Regular member, International Society on Thrombosis and Haemostasis
2008-2010: Commissioner, Korea Food & Drug Administration

Selected Publications

1)Park ES, Lim Y, Hong JT, Yoo HS, Lee CK, Pyo MY, Yun YP. Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. Vascul Pharmacol. 2010 Apr 13.
2) Lim Y, Kwon JS, Kim DW, Lee SH, Park RK, Lee JJ, Hong JT, Yoo HS, Kwon BM, Yun YP. Obovatol from Magnolia obovata inhibits vascular smooth muscle cell proliferation and intimal hyperplasia by inducing p21(Cip1). Atherosclerosis. 2010 Mar 10.
3) Lee JJ, Jin YR, Yu JY, Munkhtsetseg T, Park ES, Lim Y, Kim TJ, Pyo MY, Hong JT, Yoo HS, Kim Y, Yun YP. Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug. Atherosclerosis. 2009 Oct;206(2):375-82. 

Research Areas

1) Development of Drug for Cardiovascular Disease (심혈관질환 약물 개발)

2) Pharmacological Screening & its Mechanism of Agents for Thrombosis/ Platelet Aggregation
   (혈전질환 예방.치료제 약리활성평가 및 작용기전)

3) Pharmacological Screening & its Mechanism of Agents for Atherosclerosis/ Restenosis
   (동맥경화/혈관재협착 예방.치료제 약리활성평가 및 작용기전)


Hwan-Soo Yoo


1979-1983: BS, College of Pharmacy, Chungbuk National University
1983-1985: MS, College of Pharmacy, Seoul National University
1988-1994: Ph.D, College of Pharmacy, University of Georgia (USA)



1994-1996: Post Doc., National Institute of Health (USA)
2000-2002: Visiting Researcher, College of Medicine, Emory University (USA)
1996-present: Professor, College of Pharmacy, Chungbuk National University


Selected Publications

1) Yoo, H.S.; Hong J.T.; Lee, Y.M.; Yun, Y.P.; Lee, Y.S.; Choi, K.M.; Choi, M.H.; Ji, S.Y.; Yoo, J.M. Simultaneous HPLC Analysis of Ceramide and Dihydroceramide in Human Hairs. Arch. Pharm. Res. 2009, 32, 1795-1801.
2) Yoo, H.S.; Shin, H.W.; Kim, D.; Lee, Y.S.; Lee, B.J.; Kim, J.S.; Jang, S.; Lim, H.; Lee, Y.; Oh, S. Alteration of sphingolipid metabolism and pSTAT3 expression by dietary cholesterol in the gallbladder of hamsters. Arch. Pharm. Res. 2009, 32, 1253-1262.
3) Yoo, H.S.; Yun, Y.P.; Pyo, M.Y.; Hong J.T.; Im, J.H., Jin, Y.R.; Lee, J.J.; Yu, J.Y.; Han, X.H.; Im, S.H. Antiplatelet activity of β-carboline alkaloids from Perganum harmala: A possible mechanism through inhibiting PLCγ2 phosphorylation. Vascul. Pharmacol. 2009, 50, 147-152.


Research Areas

1) Sphingolipids?
Ceramide synthesis occurs in the endoplasmic reticulum, and is initiated by serine palmitoyltransferase, a pyridoxal 5-phosphate dependent enzyme, to produce 3-ketosphinganine which results from the condensation of serine and palmitoyl-CoA. Ceramide can be metabolized to glycosphingolipids by a glucosylceramide synthase. Sphingolipid turnover involves removal of the sugars by exoglycosidases and the phosphorylcholine of sphingomyelin by sphingomyelinase. After removal of the sphingolipid head group, Ceramide can be either reutilized for complex sphingolipid formation or undergo further breakdown processes. Ceramide at the C-1 position was phosphorylated by ceramide kinase to ceramide 1-phosphate.

2) Adipocyte Differentiation
Adipocytes are a major site for energy storage (in the form of triglycerides) for use during periods of caloric insufficiency. Adipocyte differentiation has important implications for human diseases such as type II diabetes, hypertension and coronary heart disease. Ceramide and ceramide 1-phosphate, bioactive sphingolipids, are also implicated in diverse cellular processes such as differentiation, cell proliferation, apoptosis and inflammation.

3) Antitumor Activity
Myriocin, antifungal metabolite, inhibits B16F10 melanoma cell proliferation without cytotoxicity via G2/M arrest and reduces the levels of sphingolipid metabolites. The myriocin inhibition of cell proliferation in the melanoma cells may occur by blocking the sphingolipid biosynthesis pathway and depleting sphingosine, ceramide and ceramide 1-phosphate.

Yoon-Seok Roh


2000-2008: DVM, College of Veterinary Medicine, Chonbuk National University
2008-2011: PhD, Department of Pathology, College of Veterinary Medicine, Chonbuk National University (PI: Bumseok Kim)

2012-2015: Postdoctoral Fellow (PI: Ekihiro Seki), Department of Pathology, University of California, San Diego, School of Medicine, CA, USA
2015-2016: Postdoctoral Scientist (PI: Ekihiro Seki), Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
2016-Present: Assistant Professor, College of Pharmacy, Chungbuk National University

Research Areas

I. Mitochondrial Quality Control as a Therapeutic Target in Fatty Liver and metabolic syndrome

- Mitochondrial DNA Damage Repair Responses and Ubiquitination

- Interaction between Iron and Mitochondria in Nonalcoholic Fatty Liver Disease (NAFLD)

- Gp130 and p62 in TAK1-mediated Liver Cancer development


Selected Publications

I. Primary authorships:
1. Hepatology 2014 Jul;60(1):237-49. (IF: 11.711)
2. J Clin Invest. 2014 Aug;124(8):3566-78. (IF: 13.215)
3. Gastroenterology 2015 Jan;148(1):252-254. (IF: 18.187)
4. Am J Physiol Gastrointest Liver Physiol. 2015 Jul 1;309(1):G30-41. (IF:3.798)
5. Dig Dis Sci. 2015 Jul;60(7):2009-18. (IF: 2.613)
6. J Gastroenterol. 2014 Feb;49(2):185-94. (IF: 4.414)
7. J Gastroenterol Hepatol. 2013 Aug;28 S1:38-42. (IF: 3.504)
8. Toxicol Lett. 2013 Jun 17;221(2):152-163. (IF: 3.522)
9. Toxicol Lett. 2011 Oct;206(2):218-28 (IF: 3.522)

II. Contributed authorships:
24. Nat Commun. 2014 Jul 21;5:4451. (IF: 11.329)
25. Hepatology 2014 Feb;59(2):483-95. (IF: 11.711)
26. Gastroenterology 2013 May;144(5):1042-1054. (IF: 18.187)
27. Plos One. 2014 Dec 3;9(12):e114071 (IF: 3.234)
28. Environ Toxicol Pharmacol. 2013 Nov;36(3):1087-96. (IF: 2.187)
29. Food Chem Toxicol. 2012 Oct;50(10):3537-47. (IF: 3.584)
30. Comp Immunol Microbiol Infect Dis. 2011 Jul;34(4):369-80. (IF: 2.015)
31. Vaccine. 2010 Jul;28(31):5031-7. (IF: 3.413)